Fiche du document
2023
- handle: 10670/1.ysnw33
Cairn
Mots-clés
risk-benefit non-steroidal anti-inflammatory drugs proton pump inhibitor peptic ulcer Helicobacter pylori risk-benefit non-steroidal anti-inflammatory drugs pulcer proton pump inhibitor Helicobacter pyloriSujets proches
Campylobacter pylori Medications Medicaments Prescription drugs Medicines (Drugs) Pharmaceuticals Medicine (Drugs)Citer ce document
Catherine Lamarque et al., « An update on the prevention of bleeding ulcers in 2023 », Hépato-Gastro & Oncologie Digestive, ID : 10670/1.ysnw33
Métriques
Partage / Export
Résumé
Peptic ulcer disease is a known complication in patients in intensive care units or on anticoagulants who are being given non-steroidal anti-inflammatory drugs. Screening and treatment for Helicobacter pylori should be offered to patients starting NSAID therapy. Proton pump inhibitors should be given to patients at high risk of developing a bleeding ulcer and dying from this complication.